The firm is a venture capital firm based in the Midwest focused on early-stage health technology investments with a consumer-focus. The firm is looking for companies with solutions that drive consumer engagement and health accountability (these do not have to sell D2C, most of their companies do not). The firm’s newest fund is a $150M fund, through which the firm will focus on investing in early-stage, consumer-centric digital health technologies. The firm’s initial investments generally range from $1,000,000 to $5,000,000. The firm is primarily thesis-focused and invests from Seed to Series B, with a focus just at or before the A round.
The firm is seeking digital health companies focused on the empowering consumers to be better stewards of their health and their healthcare expenditures. Accordingly, the firm is not interested in technology that solve problems solely within payers and providers, such as billing, care coordination for hospitals, or EHR platforms. The firm is indication agnostic, though has interest in chronic illnesses, social determinants, behavioral health, and personalized care among others.
The firm does not have set management team requirements. The firm will play a very active role post-investment, traditionally by taking board seats, providing key sales introductions, assisting with scaling, hiring, and providing network support.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply